keyword
https://read.qxmd.com/read/36966368/-hepatic-manifestations-of-chronic-lymphocytic-leukemia-and-correlation-with-prognosis
#1
JOURNAL ARTICLE
Ilana Levy Yurkovski, Yara Shiti, Tamar Tadmor
INTRODUCTION: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Liver function tests (LFT) revealing impairment are described in 5% of CLL patients. Although these effects are described in the literature, their occurrence at the diagnosis of CLL and correlation with prognostic data have rarely been evaluated. We aimed to evaluate the prevalence of impairment of different LFT at CLL diagnosis and its correlation with prognosis. METHODS: This is a descriptive observational retrospective study...
March 2023: Harefuah
https://read.qxmd.com/read/36966300/recent-advances-in-targeted-therapies-in-acute-myeloid-leukemia
#2
REVIEW
Rahul S Bhansali, Keith W Pratz, Catherine Lai
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease characteristics. However, the last 10 years has been marked by major advances in the molecular profiling of AML characterized by a deeper understanding of disease pathobiology and therapeutic vulnerabilities...
March 25, 2023: Journal of Hematology & Oncology
https://read.qxmd.com/read/36966266/current-therapeutic-landscape-in-lower-risk-myelodysplastic-syndromes
#3
REVIEW
Chen Wang, David A Sallman
Lower risk myelodysplastic syndromes are typically characterized by an indolent disease course with a relatively low risk of transformation into acute myeloid leukemia. These patients are classically identified using the revised International Prognostic Scoring System and most likely its molecular version in the near future which may change the paradigm of treatment. The overall goals of care are symptomatic control to reduce transfusion requirements and improve quality of life. Symptomatic anemia is the most common indication to initiate disease-specific therapies after the optimization of supportive measures...
March 25, 2023: Current Treatment Options in Oncology
https://read.qxmd.com/read/36966263/single-cell-proteogenomic-analysis-of-aberrant-monocytosis-in-tet2-mutant-premalignant-and-malignant-hematopoiesis
#4
JOURNAL ARTICLE
Terra Lasho, Christy Finke, Michael Timm, Ayalew Tefferi, Abhishek Mangaonkar, Horatiu Olteanu, Kaaren Reichard, Rhett Ketterling, Naseema Gangat, Zhuoer Xie, Jenna Fernandez, Nicholas Chia, Alexandre Gaspar-Maia, Moritz Binder, Mrinal M Patnaik
No abstract text is available yet for this article.
March 25, 2023: Leukemia
https://read.qxmd.com/read/36966262/outstanding-outcomes-with-two-low-intensity-regimens-in-children-with-low-risk-b-all-a-report-from-cog-aall0932
#5
JOURNAL ARTICLE
Reuven J Schore, Anne L Angiolillo, John A Kairalla, Meenakshi Devidas, Karen R Rabin, Patrick Zweidler-McKay, Michael J Borowitz, Brent Wood, Andrew J Carroll, Nyla A Heerema, Mary V Relling, Johann Hitzler, Nina S Kadan-Lottick, Kelly Maloney, Cindy Wang, William L Carroll, Naomi J Winick, Elizabeth A Raetz, Mignon L Loh, Stephen P Hunger
No abstract text is available yet for this article.
March 25, 2023: Leukemia
https://read.qxmd.com/read/36966261/impact-of-flt3-itd-location-on-cytarabine-sensitivity-in-aml-a-network-based-approach
#6
JOURNAL ARTICLE
Giusj Monia Pugliese, Veronica Venafra, Valeria Bica, Giorgia Massacci, Sara Latini, Simone Graziosi, Thomas Fischer, Dimitrios Mougiakakos, Martin Boettcher, Livia Perfetto, Francesca Sacco
No abstract text is available yet for this article.
March 25, 2023: Leukemia
https://read.qxmd.com/read/36966135/clonal-origin-and-development-of-high-hyperdiploidy-in-childhood-acute-lymphoblastic-leukaemia
#7
JOURNAL ARTICLE
Eleanor L Woodward, Minjun Yang, Larissa H Moura-Castro, Hilda van den Bos, Rebeqa Gunnarsson, Linda Olsson-Arvidsson, Diana C J Spierings, Anders Castor, Nicolas Duployez, Marketa Zaliova, Jan Zuna, Bertil Johansson, Floris Foijer, Kajsa Paulsson
High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal instability and showing that aneuploidy-driven malignancies are not necessarily chromosomally heterogeneous...
March 25, 2023: Nature Communications
https://read.qxmd.com/read/36966041/monoclonal-gammopathy-of-undetermined-significance-a-comprehensive-review
#8
REVIEW
Jasneet Kaur, Sai Sudha Valisekka, Maha Hameed, Pushyami Satya Bandi, Samyukta Varma, Chibuzor Joseph Onwughalu, Hany Ibrahim, Himani Mongia
Monoclonal Gammopathy of Undetermined Significance (MGUS) is an asymptomatic premalignant plasma cell dyscrasia with a predominate rise of the IgG immunoglobulin fraction without end-organ damage, often diagnosed incidentally. Despite its progression into various subsequent forms of hematological malignancies, MGUS remains underdiagnosed. A literature search was conducted using the Medline, Cochrane, Embase, and Google Scholar databases, including articles published until December 2022. Keywords used encompassed "Monoclonal Gammopathy of Undetermined Significance," "Plasma Cell dyscrasia," "Monoclonal gammopathy of renal significance," and "IgM Monoclonal gammopathy of Undetermined Significance," This study aimed to conduct a critical review to update knowledge regarding the pathophysiology, risk factors, clinical features, diagnostic protocols, complications, and current and novel treatments for MGUS...
February 23, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/36965383/viral-and-tumor-reactive-natural-killer-cells
#9
REVIEW
Jianhua Yu, Michael A Caligiuri
When we can understand what natural killer (NK) cells recognize during an encounter with an infectious pathogen or a tumor cell, and when we can understand how the NK cell responds to that encounter, we can then begin to understand the role of NK cells in human health and how to improve upon their role for the prevention and treatment of human disease. In the quest to understand how these cells function in antiviral and antitumoral immunity, there have been previously described mechanisms established for NK cells to participate in clearing viral infections and tumors, including classical NK cell antibody dependent cellular cytotoxicity (ADCC) as well as recognition and elimination of transformed malignant cells through direct ligand interactions...
March 23, 2023: Seminars in Immunology
https://read.qxmd.com/read/36965231/synergetic-effect-of-azacitidine-and-sorafenib-in-treatment-of-a-case-of-myeloid-neoplasm-with-sole-chromosomal-abnormality-t-8-22-p11-2-q11-2-bcr-fgfr1-rearrangement
#10
Somprakash Dhangar, Chandrakala Shanmukhaiah, Leena Sawant, Jagdeeshwar Ghatanatti, Aditi Shah, Leo Prince Mathan S, Babu Rao Vundinti
The sole t(8;22)(p11.2;q11.2)/BCR- FGFR1 chromosomal abnormality formerly known as aCML is an extremely rare disease entity with a history of rapid progression. Though patients resemble phenotypically chronic myeloid leukemia, the treatment of patients with sole BCR-FGFR1 rearrangement are still challenging for clinicians due to rapid progressive nature and unavailability of uniform treatment guidelines. In present case study, we describe a case of myeloid neoplasm with sole chromosomal abnormality of t(8;22)(p11...
March 18, 2023: Cancer Genetics
https://read.qxmd.com/read/36965095/evaluation-of-diagnostic-efficacy-of-nrp-1-cd304-in-hematological-diseases
#11
JOURNAL ARTICLE
Yi-Jun Liu, Xiao-Hui Li, Yi-Ling Song, Yi-Chen Zhou, Rong-Zeng Cai, Pei-Dong Chi
BACKGROUND: Previous studies had explored the diagnostic or prognostic value of NRP-1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B-cell acute lymphoblastic leukemia (B-ALL), whereas the expression and application value of NRP-1/CD304 in other common hematological diseases have not been reported. METHODS: Bone marrow samples from 297 newly diagnosed patients with various hematological diseases were collected to detect the expression of NRP-1/CD304 by flow cytometry (FCM)...
March 25, 2023: Cancer Medicine
https://read.qxmd.com/read/36964941/delineation-of-clinical-course-outcomes-and-prognostic-factors-in-patients-with-t-cell-prolymphocytic-leukemia
#12
JOURNAL ARTICLE
Ashley Rose, Ling Zhang, Akriti G Jain, Abida Poovathukaran Babu, Lubomir Sokol, Hayder Saeed, Qianxing Mo, Wenyi Fan, Xiaohui Zhang
T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T cell neoplasm with a diverse clinical course. T-PLL is typically associated with a poor prognosis; however, a subset of patients have inactive disease on initial presentation. There is a lack of accurate delineation of the disease based on initial clinical presentation and pathological assessment, hindering clinical decision-making. To characterize and delineate disease subtypes based on initial clinical presentation and pathologic assessment, we retrospectively reviewed 81 patients with T-PLL treated at our institution...
March 25, 2023: American Journal of Hematology
https://read.qxmd.com/read/36964937/relationship-between-comorbidities-mutational-profile-and-outcome-after-intensive-chemotherapy-in-patients-older-than-60%C3%A2-years-with-acute-myeloid-leukemia-assessment-of-different-risk-scores
#13
JOURNAL ARTICLE
Amélie Bachelot, Anne Bouvier, Jérémie Riou, Sylvain Thepot, Aurélien Giltat, Christopher Nunes Gomes, Jérôme Paillassa, Rébecca Jouanneau-Courville, Maxime Renard, Annaelle Beucher, Laurane Cottin, Margaux Wiber, Bénédicte Ribourtout, Franck Geneviève, Damien Luque Paz, Aline Tanguy-Schmidt, Valérie Ugo, Mathilde Hunault-Berger, Odile Blanchet, Corentin Orvain
The aim of this study was to evaluate how comorbidities and molecular landscape relate to outcome in patients with acute myeloid leukemia (AML) aged 60 years or older who received intensive induction therapy. In 91 patients, 323 mutations were identified in 77 genes by next-generation sequencing, with a median of four mutations per patient, with NPM1, FLT3, TET2, and DNMT3A being the most frequently mutated genes. A multistate model identified FLT3, IDH2, RUNX1, and TET2 mutations as associated with a higher likelihood of achieving complete remission while STAG2 mutations were associated with primary refractory disease, and DNMT3A, FLT3, IDH2, and TP53 mutations with mortality after relapse...
March 25, 2023: American Journal of Hematology
https://read.qxmd.com/read/36964890/fertility-status-in-childhood-cancer-survivors-of-hematological-malignancies-a-systematic-review
#14
REVIEW
Maria A Karalexi, Adamantia Kontogeorgi, George Papaioannou, Spyridoula Neofytou, Pantelis Messaropoulos, Maria Moschovi, Sophia N Kalantaridou
Stunning advances in treatment modalities implemented in children with hematological malignancies have led to 5-year overall survival rates exceeding 85%. However, this growing population of long-term survivors has raised significant concerns about their fertility status throughout adulthood, while specific treatment- and non-treatment-related factors appear to possibly affect fertility through distinct mechanisms. We aimed to comprehensively review the published literature on the association between treatment-related factors and risk of impaired fertility in childhood hematological cancer survivors...
March 25, 2023: Hormones: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/36964839/acute-pancreatitis-as-the-initial-manifestation-of-acute-myeloid-leukemia-with-chromosome-16-rearrangements
#15
JOURNAL ARTICLE
Hidehito Fukushima, Ken Morita, Masako Ikemura, Mariko Tanaka, Yudai Nakai, Hiroaki Maki, Tatsunori Suzuki, Suguru Mizuno, Yousuke Nakai, Mineo Kurokawa
Acute pancreatitis is an acute inflammatory process of the pancreas that is becoming an increasingly common clinical issue. The most frequent underlying etiologies include gallstones and chronic alcohol use, which account for more than two-thirds of cases. We recently experienced a rare case of acute myeloid leukemia (AML) presenting with recurrent acute pancreatitis, which we later discovered was caused by diffusely infiltrating extramedullary sarcoma in the pancreas. Comprehensive analysis of previous cases of AML presenting as acute pancreatitis suggested involvement of cytogenetic alterations in chromosome 16 in its pathogenesis...
March 25, 2023: International Journal of Hematology
https://read.qxmd.com/read/36964818/efficacy-of-epigenetic-agents-for-older-patients-with-acute-myeloid-leukemia-and-myelodysplastic-syndrome-in-randomized-controlled-trials-a-systematic-review-and-network-meta-analysis
#16
JOURNAL ARTICLE
SuA Oh, EunYoung Kim
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that mostly affect the elderly and have poor prognoses. Mutations in epigenetic regulatory genes cause AML/MDS through changes in DNA methylation and histone modifications. Some epigenetic agents are used in patients with AML and MDS. However, most studies have focused on azacitidine (AZA) or decitabine (DEC), and few studies have been conducted on combination therapies or other epigenetic therapies. This network meta-analysis (NMA) aimed to compare the efficacy of epigenetic agents overall in patients with AML and MDS...
March 25, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/36964663/runx1-together-with-dat-mutations-predicted-poor-outcome-in-acute-myeloid-leukemia
#17
JOURNAL ARTICLE
Jinyan Xiao, Jundan Xie, Biqi Zhou, Yujie Liu, Jing Lu, Airui Jiang, Hong Yao, Qiaocheng Qiu, Zixuan Ding, Shengli Xue, Xiaowen Tang, Huiying Qiu, Suning Chen, Hongjie Shen, Depei Wu, Yang Xu
We retrospectively explored the prognostic impact of DAT mutations at diagnosis in 122 RUNX1mut AML patients. RUNX1 missense mutation was dominant in the RUNT domain, and frameshift mutation was dominant in the TAD domain. DAT mutations occurred in 38.5% of RUNX1mut AML. After propensity score matching, DATpos patients had worse two-year relapse-free survival (RFS) than DATneg patients ( p  = .041). Moreover, RUNX1high (VAF ≥ 37.6%) patients showed poorer two-year overall survival (OS) and RFS than RUNX1low (VAF < 37...
March 24, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/36964223/effects-of-post-transplant-maintenance-therapy-with-decitabine-prophylaxis-on-the-relapse-for-acute-lymphoblastic-leukemia
#18
JOURNAL ARTICLE
Jixin Fan, Runqing Lu, Jingkui Zhu, Xiao Guo, Dingming Wan, Xinsheng Xie, Weijie Cao, Yinyin Zhang, Haiqiu Zhao, Yingmei Li, Rongqun Guo, Zhongxing Jiang, Yongping Song, Fei He, Rong Guo
In adults with acute lymphoblastic leukemia (ALL), post-transplant relapse is a major risk factor for mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our study investigated the efficacy and safety of decitabine (dec) with ALL patients post-transplantation. We performed a retrospective cohort study to assess the efficacy of decitabine (dec) with post-transplant ALL at the First Affiliated Hospital of Zhengzhou University from February 2016 to September 2021. A total of 141 consecutive ALL patients were analyzed and divided into decitabine (dec, n = 65) and control (ctrl, n = 76) groups based on whether they were treated with decitabine after allo-HSCT...
March 24, 2023: Bone Marrow Transplantation
https://read.qxmd.com/read/36964195/prediction-model-for-drug-response-of-acute-myeloid-leukemia-patients
#19
JOURNAL ARTICLE
Quang Thinh Trac, Yudi Pawitan, Tian Mou, Tom Erkers, Päivi Östling, Anna Bohlin, Albin Österroos, Mattias Vesterlund, Rozbeh Jafari, Ioannis Siavelis, Helena Bäckvall, Santeri Kiviluoto, Lukas M Orre, Mattias Rantalainen, Janne Lehtiö, Sören Lehmann, Olli Kallioniemi, Trung Nghia Vu
Despite some encouraging successes, predicting the therapy response of acute myeloid leukemia (AML) patients remains highly challenging due to tumor heterogeneity. Here we aim to develop and validate MDREAM, a robust ensemble-based prediction model for drug response in AML based on an integration of omics data, including mutations and gene expression, and large-scale drug testing. Briefly, MDREAM is first trained in the BeatAML cohort (n = 278), and then validated in the BeatAML (n = 183) and two external cohorts, including a Swedish AML cohort (n = 45) and a relapsed/refractory acute leukemia cohort (n = 12)...
March 24, 2023: NPJ Precision Oncology
https://read.qxmd.com/read/36964168/type-i-interferon-signaling-in-malignant-blasts-contributes-to-treatment-efficacy-in-aml-patients
#20
JOURNAL ARTICLE
Peter Holicek, Iva Truxova, Jana Rakova, Cyril Salek, Michal Hensler, Marek Kovar, Milan Reinis, Romana Mikyskova, Josef Pasulka, Sarka Vosahlikova, Hana Remesova, Iva Valentova, Daniel Lysak, Monika Holubova, Petr Kaspar, Jan Prochazka, Lenka Kasikova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova
While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor microenvironment promotes cancer immunosurveillance and contributes to the efficacy of various antineoplastic agents, notably immunogenic cell death inducers. Here, we report that malignant blasts from patients with acute myeloid leukemia (AML) release type I IFN via a Toll-like receptor 3 (TLR3)-dependent mechanism that is not driven by treatment...
March 24, 2023: Cell Death & Disease
keyword
keyword
1190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.